NetworkNewsBreaks – Lexaria Bioscience Corp.’s
Post# of 721
Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) is leveraging the need for speed in the likes of Formula One racing with its innovative drug delivery platform. A recent article discussing the company’s DehydraTECH™ reads, “In recent in vivo tests, the technology delivered 203 nanograms per milliliter (ng/mL) of nicotine in 15 minutes, 70 percent more than the control. Such rapidity may rival smoking; particularly as new research (http://nnw.fm/PMz57) suggests that ‘nicotine takes much longer than previously thought to reach peak levels in the brains of cigarette smokers.’ For tobacco industry giants on the search for safer delivery methods than smoking, the DehydraTECH™ platform is increasingly beginning to look like an attractive alternative.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer